Physician profile
Arman Ossia
NPI 1811151681
$4,641.29
in general payments reported to CMS, 2019-2025
29 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $331 · 2021: $386 · 2022: $406 · 2023: $137 · 2024: $857 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,475.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,232.43 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $674.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $359.47 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $357.88 | 2023-2024 | Voquezna |
| Novo Nordisk INC | $267.66 | 2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $208.58 | 2019-2023 | Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $171.08 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Kowa Pharmaceuticals America, INC. | $167.06 | 2025 | Zoryve |
| Amgen INC. | $165.58 | 2025 | Otezla, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.16 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $143.05 | 2019-2025 | Farxiga |
| Intuitive Surgical, INC. | $126.00 | 2025 | |
| Stryker Corporation | $112.65 | 2024 | Insignia |
| Amarin Pharma, INC. | $58.19 | 2019-2022 | |
| Pfizer INC. | $56.33 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $47.01 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $43.82 | 2020 | |
| Gilead Sciences, INC. | $34.86 | 2024 | |
| Exact Sciences Corporation | $33.15 | 2023 | Cologuard Collection Kit |
| Fidia Pharma USA INC. | $30.38 | 2024 | Hyalgan, Hymovis, Triluron |
| Celgene Corporation | $24.61 | 2019 | |
| Boston Scientific Corporation | $24.29 | 2024 | |
| Dermira, INC. | $23.90 | 2020 | |
| Astellas Pharma US INC | $23.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.46 | 2019 | |
| Vertiflex, INC. | $18.91 | 2019 | |
| Horizon Therapeutics Plc | $17.93 | 2020 | |
| Eyevance Pharmaceuticals LLC | $16.73 | 2021 | |
| Hikma Pharmaceuticals USA | $16.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arman Ossia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.